ALDX vs HALO

Halozyme Therapeutics, Inc.

(HALO) offers the better valuation at 25. 9x trailing P/E (8. 2x forward), making it the more compelling value choice. Analysts rate Aldeyra Therapeutics, Inc. (ALDX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Halozyme Therapeutics, Inc.

is actually cheaper at 8. 2x.

Over the past 5 years, Halozyme Therapeutics, Inc.

(HALO) delivered a total return of +39. 1%, compared to -85. 6% for Aldeyra Therapeutics, Inc. (ALDX). Over 10 years, the gap is even starker: HALO returned +598. 4% versus ALDX's -71. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Aldeyra Therapeutics, Inc. 's 1. 45β — meaning ALDX is approximately 160% more volatile than HALO relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Halozyme Therapeutics, Inc.

grew EPS -25. 4% year-over-year, compared to -46. 9% for Aldeyra Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus 0. 0% for Aldeyra Therapeutics, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for ALDX. At the gross margin level — before operating expenses — HALO leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 2x forward P/E versus 24. 9x for Aldeyra Therapeutics, Inc. — 16. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALDX: 455. 7% to $9. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +598. 4% 10Y return). Both have compounded well over 10 years (HALO: +598. 4%, ALDX: -71. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ALDX is a small-cap quality compounder stock; HALO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.